Oncimmune Signs Agreement with Accu Reference
News Mar 22, 2016
Oncimmune has announced a multi-year partnership with Accu Reference Medical lab provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. Accu Reference will offer Oncimmune’s EarlyCDT®-Lung test to its rapidly growing physician account base in over 15 states including primary care physicians and pulmonologists for use with low dose computed tomography (CT) lung cancer screening programs. No financial details are disclosed.
EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer. The test measures a panel of seven autoantibodies to detect the presence of lung cancer and has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
Greg Stanley, President of Commercial Operations, Oncimmune said: “This agreement will allow more physicians to access the EarlyCDT-Lung test and provide patients at risk of developing lung cancer with information that could positively impact their health.”
"Accu Reference Medical Lab continues to be a leader in bringing innovative diagnostic tools to our clients and we look forward to offering EarlyCDT-Lung,” said Konstantin Bas, CEO of Accu Reference. “EarlyCDT-Lung offers a complementary approach to annual CT screening and we believe it has the potential to make a real difference in the risk assessment and early detection of lung cancer.”
EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results were recently presented at the 16th World Conference on Lung Cancer; showing a high cancer detection rate with the majority of these cancers being early stage, resulting in better than expected test performance.
Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosisREAD MORE
A skin swab test for Parkinson's has become a real possibility, after mass spectrometry was used to detect altered levels of specific compounds on the skin of people with the condition. The research is a result of the incredible ability of one woman to detect a unique odor on the skin of people with Parkinson's disease. These findings open the door to a non-invasive screening test.READ MORE